These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26799423)

  • 1. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation.
    Bouhlal H; Ouled-Haddou H; Debuysscher V; Singh AR; Ossart C; Reignier A; Hocini H; Fouquet G; Al Baghami M; Eugenio MS; Nguyen-Khac E; Regimbeau JM; Marcq I
    Oncotarget; 2016 Mar; 7(9):9832-43. PubMed ID: 26799423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
    Wang XQ; Zhu YQ; Lui KS; Cai Q; Lu P; Poon RT
    Clin Cancer Res; 2008 Nov; 14(21):6813-20. PubMed ID: 18980975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
    Tian L; Yao K; Liu K; Han B; Dong H; Zhao W; Jiang W; Qiu F; Qu L; Wu Z; Zhou B; Zhong M; Zhao J; Qiu X; Zhong L; Guo X; Shi T; Hong X; Lu S
    Oncogene; 2020 Apr; 39(15):3145-3162. PubMed ID: 32060423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
    Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
    Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression.
    Marcq I; Nyga R; Cartier F; Amrathlal RS; Ossart C; Ouled-Haddou H; Ghamlouch H; Galmiche A; Chatelain D; Lamotte L; Debuysscher V; Fuentes V; Nguyen-Khac E; Regimbeau JM; Marolleau JP; Latour S; Bouhlal H
    PLoS One; 2013; 8(12):e82918. PubMed ID: 24376606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs.
    Fouquet G; Debuysscher V; Ouled-Haddou H; Eugenio MS; Demey B; Singh AR; Ossart C; Al Bagami M; Regimbeau JM; Nguyen-Khac E; Naassila M; Marcq I; Bouhlal H
    Oncotarget; 2016 May; 7(22):32493-503. PubMed ID: 27081035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.
    Pellegrino R; Calvisi DF; Ladu S; Ehemann V; Staniscia T; Evert M; Dombrowski F; Schirmacher P; Longerich T
    Hepatology; 2010 Mar; 51(3):857-68. PubMed ID: 20112253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
    Mok WC; Wasser S; Tan T; Lim SG
    World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.
    Shtivelman E
    Mol Cancer Res; 2003 Nov; 1(13):959-69. PubMed ID: 14638868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsa-let-7b inhibits cell proliferation by targeting PLK1 in HCC.
    He Z; Deng W; Jiang B; Liu S; Tang M; Liu Y; Zhang J
    Gene; 2018 Oct; 673():46-55. PubMed ID: 29913237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associated with Poor Prognosis.
    Li R; Jiang X; Zhang Y; Wang S; Chen X; Yu X; Ma J; Huang X
    Arch Med Res; 2019 Jan; 50(1):10-17. PubMed ID: 31101236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
    Chen XJ; Wu LM; Xu XB; Feng XW; Xie HY; Zhang M; Shen Y; Wang WL; Liang TB; Zheng SS
    Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1354-8. PubMed ID: 18241575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis.
    Eckerdt F; Strebhardt K
    Cancer Res; 2006 Jul; 66(14):6895-8. PubMed ID: 16849530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation.
    Lin XT; Yu HQ; Fang L; Tan Y; Liu ZY; Wu D; Zhang J; Xiong HJ; Xie CM
    Elife; 2021 Nov; 10():. PubMed ID: 34779401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S; Ahmad N
    FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression.
    Studach LL; Rakotomalala L; Wang WH; Hullinger RL; Cairo S; Buendia MA; Andrisani OM
    Hepatology; 2009 Aug; 50(2):414-23. PubMed ID: 19472310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
    Choi M; Kim W; Cheon MG; Lee CW; Kim JE
    Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo-like kinase 1 is essential for the first mitotic division in the mouse embryo.
    Baran V; Solc P; Kovarikova V; Rehak P; Sutovsky P
    Mol Reprod Dev; 2013 Jul; 80(7):522-34. PubMed ID: 23649868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
    He Z; Wu J; Dang H; Lin H; Zheng H; Zhong D
    Cancer Lett; 2011 Apr; 303(2):92-8. PubMed ID: 21330050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.